Abstract:Xun Wang, 1, * Xiao Li, 1, * Haifa Guo, 1, * Lingxiang Zhu, 2 Zhiyong Peng, 3 Jun Wang, 1 Fan Yang, 1 Yong Guo 4 1 Department of Thoracic Surgery, Peking University People's Hospital, Peking University, Beijing 100044, People's Republic of China; 2 National Research Institute for Health and Family Planning, Beijing 100081, People's Republic of China; 3 TargetingOne Corporation, Beijing 100190, People's Republic of China; 4 Department of Biomedical Engineering, School of Medicine, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Tsinghua University, Beijing 100084, People's Republic of China *These authors contributed equally to this work Correspondence: Fan Yang Department of Thoracic Surgery, Peking University People's Hospital, Peking University, Beijing 100044, People's Republic of China Email yangfanpkuph@sina.com Yong Guo Department of Biomedical Engineering, School of Medicine, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Tsinghua University, Beijing 100084, People's Republic of China Email yongguo@tsinghua.edu.cn Objective: The aim of this study was to investigate the allelic relation between de novo T790M and concomitant sensitizing EGFR mutations in EGFR-TKIs naïve NSCLCs and to explore whether the formalin-fixed and paraffin-embedded (FFPE) materials affect the detection of de novo T790M mutation. Methods: Specimens of 300 consecutive EGFR-TKI naïve NSCLCs who received surgical resection between January 2016 and June 2018 were retrospectively investigated. All the snap-frozen tumor tissues from 300 NSCLCs were screened by droplet digital PCR (ddPCR) for the detection of de novo T790M mutation. The allelic relation between de novo T790M mutation and concomitant sensitizing EGFR mutations was also investigated. Furthermore, we assessed de novo T790M mutation in paired FFPE specimens of 50 patients which included tumor tissues and paired normal lung tissues of the pretreatment NSCLCs to investigate whether FFPE materials affect the detection of de novo T790M mutation. Results: The de novo T790M mutation was observed in four patients which included one patient of single de novo T790M mutation and three patients of de novo T790M mutation coexisting with L858R mutation. The incidence of de novo T790M in pretreatment NSCLCs who harboring EGFR mutations was 2.9% (4/139). All the de novo T790M mutations were detected in cis with the concomitant L858R mutations for the three NSCLCs. Our ddPCR method demonstrated that the frequency of de novo T790M mutation was ranging from 0.1% to 0.5% among 90% (45/50) of the FFPE tumor samples and 92% (46/50) of the paired FFPE adjacent normal lung samples. The frequency of de novo T790M mutation in the paired snap-frozen samples was all below 0.1%. Conclusion: Our study demonstrated that most de novo T790M mutations were detected in cis with concomitant sensitizing mutations for pretreatment NSCLCs. Analytical cut-off of ddPCR assay for FFPE specimens should be validated carefully considering the possibility of FFPE-derived artificial gene mutations. Keywords: non-small cell lung cancer, NSCLC, droplet digital PCR, de novo T790M, acquired T790M, EGFR mutation

Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs

Sputum cell-free DNA: Valued surrogate sample for the detection of <i>EGFR</i> exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs

Sputum Cell-Free DNA <i>Valued Surrogate Sample for Detection of</i> EGFR <i>Mutation in Patients with Advanced Lung Adenocarcinoma</i>

Detection of EGFR Gene Mutation Status from Pleural Effusions and Other Body Fluid Specimens in Patients with Lung Adenocarcinoma

Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy

Liquid Biopsies Using Pleural Effusion-Derived Exosomal DNA in Advanced Lung Adenocarcinoma.

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC

Highly Sensitive Droplet Digital PCR Method for Detection of de novo EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer

Comparative Study of EGFR Mutations Detected in Malignant Pleural Effusion, Plasma and Tumor Tissue in Patients with Adenocarcinoma of the Lung

P3.02b-098 Plasma T790M Mutation Associates with Extensive Progression in Non-small Cell Lung Cancer with Acquired Resistance to EGFR Inhibitors: Topic: EGFR RES

Non-invasive and Quantitative Analysis for EGFR T790M Mutation in the Patients with Advanced Non-Small Cell Lung Cancer Received EGFR-TKI Therapy.

Analysis of Egfr Mutation Status in Tissue and Plasma for Predicting Response to Egfr-Tkis in Advanced Non-Small-Cell Lung Cancer

Sputum cell-free DNA for detection of alterations of multiple driver genes in lung adenocarcinoma

Assessment of EGFR Mutations in Plasma from Advanced NSCLC Patients by Modified Cell-Free DNA Extraction Method and Blocker PCR Assays

Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma

Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example

Comparison of Egfr Signaling Pathway Somatic Dna Mutations Derived from Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology

Value of Malignant Pleural Effusion Supernatants (mpes) in Epidermal Growth Factor Receptor (EGFR) Mutation Detection of Patients with Advanced Lung Adenocarcinoma (ADC).

Different First Line EGFR-TKI Regimen and the Clearance of EGFR Sensitive Mutation in Acquired EGFR-TKI Resistant Lung Adenocarcinoma Patients